Abbott Laboratories (ABT)
Abbott plans marketing push for glucose monitors beyond diabetes
Abbott Laboratories will use a mix of TV advertisements and guerilla marketing as well as seek to personalize health data to tap people without diabetes for the U.S. launch of its glucose monitoring device, CEO Robert Ford said on Thursday.
Should you buy Abbott stock? CEO sees multi-billion dollar opportunity in new product
Abbott Laboratories (NYSE: ABT) faced a 3.0% decline in stock price this morning despite reporting a strong second quarter and raising its full-year guidance. Meanwhile, CEO Robert B.
Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT ) Q2 2024 Earnings Conference Call July 18, 2024 9:00 AM ET Company Participants Robert Ford - Chief Executive Officer Phil Boudreau - Executive Vice President, Finance, Chief Financial Officer Mike Comilla - Vice President, Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Travis Sneed - Bank of America Robbie Marcus - JP Morgan Josh Jennings - TD Cowen David Roman - Goldman Sachs Danielle Antalffy - UBS Vijay Kumar - Evercore ISI Operator Good morning and thank you for standing by. Welcome to Abbott's second quarter 2024 earnings conference call.
Jobless Claims Increased More Than Expected
Another Thursday morning, another Weekly Jobless Claims report. On an Initial Claims basis, we jump back up to where we were two weeks ago, to +243K new claims — a near-term high going back to August of last year.
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.
Compared to Estimates, Abbott (ABT) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Abbott (ABT) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.08 per share a year ago.
2 Healthcare Stocks For Your Mid-July 2024 Watchlist
Healthcare stocks to check out in the stock market right now.
Why This Leading Health Stock is a Buy No Matter the Market Move
Abbott Laboratories NYSE: ABT is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It's not always a good buy; all healthcare stocks have ups and downs in their cycles, but Abbott is a buy today, no matter how it moves.
Abbott raises annual profit forecast as strong medical device sales power quarterly beat
Abbott Laboratories raised its annual profit forecast on Thursday and beat Wall Street estimates for second-quarter earnings, buoyed by strong sales of its cardiac and diabetes devices.
2 Dividend Stocks to Buy and Hold Forever
Microsoft and Abbott Laboratories have been leaders in their respective industries for decades. Both companies have important growth opportunities and impressive innovative abilities.
Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18.
